Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Drugs. 2023 Nov;83(16):1537-1541. doi: 10.1007/s40265-023-01947-9.
Lotilaner ophthalmic solution 0.25% (XDEMVY™), a gamma-aminobutyric acid-gated chloride channel (GABA-Cl) inhibitor selective for mites, is being developed by Tarsus Pharmaceuticals for the treatment of Demodex blepharitis and meibomian gland dysfunction in patients with Demodex lid infestation (Demodex-induced meibomianitis). On 24 July 2023, lotilaner ophthalmic solution 0.25% received its first approval in the USA for the treatment of Demodex blepharitis. The agent is also currently in phase 3 development for Demodex blepharitis in China and phase 2 development for Demodex-induced meibomianitis in the USA. This article summarizes the milestones in the development of lotilaner ophthalmic solution 0.25% leading to this first approval for the treatment of Demodex blepharitis in the USA.
Lotilaner 眼科溶液 0.25%（XDEMVY™）是一种γ-氨基丁酸门控氯离子通道（GABA-Cl）抑制剂，对螨虫具有选择性，由 Tarsus Pharmaceuticals 开发用于治疗螨虫性睑缘炎和伴有螨虫定植的患者的睑板腺功能障碍（螨虫性睑板腺炎）。2023 年 7 月 24 日，Lotilaner 眼科溶液 0.25%在美国获得首个用于治疗螨虫性睑缘炎的批准。该药物目前也正在中国进行螨虫性睑缘炎的 3 期开发，以及在美国进行螨虫性睑板腺炎的 2 期开发。本文总结了导致 lotilaner 眼科溶液 0.25%在美国首次获批用于治疗螨虫性睑缘炎的发展里程碑。
